Tacrolimus To Treat Pyoderma Gangrenosum Resistant to Cyclosporine
Authors: Renata D'Inca
Journal: Annals of Internal Medicine (1998)

Letters1 May 1998Tacrolimus To Treat Pyoderma Gangrenosum Resistant to CyclosporineRenata D'Inca, MD, Stefano Fagiuoli, MD, and Giacomo Carlo Sturniolo, MDRenata D'Inca, MDUniversity of Padua; 35127 Padua, Italy, Stefano Fagiuoli, MDUniversity of Padua; 35127 Padua, Italy, and Giacomo Carlo Sturniolo, MDUniversity of Padua; 35127 Padua, ItalyAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-9-199805010-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Steroids and, recently, cyclosporine, are effective in the treatment of most pyodermic lesions [1]. Tacrolimus, a new immunosuppressive drug, inhibits T-cell activation by blocking receptor-mediated signal transduction pathways [2, 3].A 30-year-old man developed ileocolonic Crohn disease complicated by perianal fistula in 1984. After two ileal resections, he received maintenance therapy with sulfasalazine (4 g/d) until May 1996, when steroid therapy was started for a clinical relapse. On 25 July 1996, the patient noted diarrhea with purulent discharge from his perianal fistula and developed painful swelling and a synovial effusion of the right knee. Soon after, a ...References1. Hughes JR, Smith E, Higgins EM, Berry H, du Vivier AW. Pyoderma gangrenosum in a patient with rheumatoid arthritis responding to treatment with cyclosporin A. Br J Rheum. 1994; 33:680-1. Google Scholar2. Abu Elmagd K, Jegasothy BV, Ackerman CD, Thomson AW, Rilo H, Nikolaidis N, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc. 1991; 23:3328-9. Google Scholar3. Cooley HM, Castelino D, McNair P, Russell DM, Chohan V, Kay TW, et al. Resolution of pyoderma gangrenosum using tacrolimus (FK-506). Aust N Z J Med. 1996; 26:238-9 Google Scholar Author, Article, and Disclosure InformationAuthors: Renata D'Inca, MD; Stefano Fagiuoli, MD; Giacomo Carlo Sturniolo, MDAffiliations: University of Padua; 35127 Padua, Italy PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and TreatmentCanakinumab in adults with steroid‐refractory pyoderma gangrenosumManagement of neutrophilic dermatosesExtraintestinal Manifestations of Inflammatory Bowel DiseasesBasic immunosuppressive drugs outside solid organ transplantationExtraintestinal Manifestations of Inflammatory Bowel DiseaseTopical Tacrolimus Therapy for Pyoderma GangrenosumSkin complications associated with inflammatory bowel diseaseTopical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn's disease: report of two casesWhen is Recalcitrant Pyoderma Gangrenosum Truly Recalcitrant?Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel diseaseNew immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indicationsExtraintestinal complications of inflammatory bowel diseaseTacrolimus in Dermatologic DisordersIntravenous Cyclosporine in Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel DiseaseCYCLOSPORINE AND TACROLIMUS IN DERMATOLOGYA Rationale for Adjuvant Surgical Intervention in Pyoderma GangrenosumApplications of tacrolimus for the treatment of skin disordersRecalcitrant pyoderma gangrenosum treated with systemic tacrolimus 1 May 1998Volume 128, Issue 9Page: 783-784KeywordsFistulasInflammationKneesLesionsPatient advocacyPyodermaSteroid therapySteroidsTemperatureUlcers ePublished: 15 August 2000 Issue Published: 1 May 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...